AX-2026-042427

ARA-290 · 2 mg declared · Hunan Aslsen Technology Co., Ltd. · lot HOMO-2602-K4395

PASSPURITY ONLY

Report ID: AX-2026-042427
Compound: ARA-290
Compound class: Tissue-repair and immunomodulatory peptides
Supplier: Homopeptide — Hunan Aslsen Technology Co., Ltd.
Batch / lot: HOMO-2602-K4395
Declared label claim: 2mg
Laboratory: Janoshik Analytical
Assay date: 08 Jan 2026
Submitted: 12 Jan 2026
Quarter: 2026-Q1
Submitter: z.mwangi
Sample provenance: Buyer-sourced

Section 1

Results

Measured against the index acceptance specification for the tissue-repair and immunomodulatory peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 30 min gradient, 214 nm	99.43	% area	≥ 98.0	PASS
Total impurities	RP-HPLC, sum of reported peaks	0.57	% area	≤ 2.0	PASS
Largest single impurity	RP-HPLC — acetyl adduct (+42 Da)	0.21	% area	≤ 1.00	PASS
Identity	not ordered on this submission	not determined	—	required for VERIFIED status	NOT TESTED
Peptide content	not ordered on this submission	not determined	—	required to check label claim	NOT TESTED
Water content	Karl Fischer, coulometric, duplicate	4.46	%	≤ 10.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	4.98	%	≤ 12.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.97	%	—	NOT TESTED
Endotoxin	kinetic chromogenic LAL	1.46	EU/mg	≤ 5.0	PASS
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	Off-white lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear, colourless, no visible particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	5.18	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 30 min gradient	8.67	min	8.72 ± 0.25 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.26	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	83,373	—	≥ 20,000	PASS
Resolution to nearest impurity	vs [D-Ser]-diastereomer	0.97	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 30 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 83,373, and skew follows the reported asymmetry factor of 1.26. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.21 % impurity against a 99.43 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	ARA-290 — main peak	8.67	4,832,606	99.43	—
2	acetyl adduct (+42 Da)	9.07	10,207	0.21	+42.011
3	[D-Ser]-diastereomer	8.55	7,776	0.16	0.000
4	deamidated (+1 Da)	8.45	4,860	0.10	+0.984
5	des-Gln truncate (−128 Da)	8.37	4,860	0.10	-128.059
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	99.67	99.43	divergence +0.25 pp vs batch median
Total impurities (% area)	0.33	0.57
Largest single impurity (% area)	not stated	0.21
Water (%)	3.1	4.46
Counter-ion (%)	4.9	4.98
Peptide content (%w/w)	91.4	not determined
Endotoxin (EU/mg)	not stated	1.46
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Retail purchase → submitter (2–8 °C, 26 d) → laboratory (courier, ambient, 5 d) → assay.
Assay date: 08 Jan 2026
Submitted to the index: 12 Jan 2026
Laboratory: Janoshik Analytical, Ostrava, Czechia
Method basis: 30 min gradient · high-resolution MS
Verification status: PURITY ONLY

What this report does not establish

That the compound is the compound named. No identity confirmation was ordered on this submission. A purity figure describes chromatographic homogeneity of whatever eluted; it does not name it.
How much of the named compound is in the vial. Peptide content was not determined, so recovered mass cannot be calculated and the label claim cannot be checked.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 3

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

buyer_sourced12 Jan 2026

Anyone can generate one of these. That is the argument the index makes on its submission page and it is the reason the dataset grows without any supplier's cooperation.

Contributor #G-886912 Jan 2026

Where the nearest species is a diastereomer of ARA-290, resolution is the only thing that separates them at all — no mass measurement will. The compound fingerprint states what is achievable and on what method.

valley_drop12 Jan 2026

Valley height relative to the smaller peak is the practical criterion an operator uses, and it is not on the report. Resolution is a proxy for it and an imperfect one on asymmetric pairs.

Section 7

Related records

Same batch — lot HOMO-2602-K4395 n=9

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042426	HOMO-2602-K4395	Janoshik	2026-Q1	99.93	4.42	106.3	Buyer-sourced	0	PASS
AX-2026-042428	HOMO-2602-K4395	Janoshik	2026-Q1	99.42	4.54	92.9	Buyer-sourced	0	PASS
AX-2026-042429	HOMO-2602-K4395	PeptideMeter	2026-Q1	99.29	3.82	102.2	Buyer-sourced	0	PASS
AX-2026-042430	HOMO-2602-K4395	Janoshik	2026-Q1	99.20	4.23	104.8	Buyer-sourced	0	PASS
AX-2026-042431	HOMO-2602-K4395	PeptideMeter	2026-Q1	99.50	3.85	101.8	Buyer-sourced	0	PASS
AX-2026-042432	HOMO-2602-K4395	Janoshik	2026-Q1	99.40	3.91	—	Buyer-sourced	0	PASS
AX-2026-042433	HOMO-2602-K4395	Medutest	2026-Q1	99.93	4.10	99.9	Buyer-sourced	1	FAIL
AX-2026-042434	HOMO-2602-K4395	PeptideMeter	2026-Q1	99.22	3.64	94.1	Buyer-sourced	0	PASS

Batch rollup and reproducibility assessment →

Cross-sections

Other recent ARA-290 records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Result
AX-2026-041767	ASY	ASY-{CAT}-1521	Janoshik	2026-Q3	99.66	4.42	103.7	Buyer-sourced	PASS
AX-2026-043222	SGN	SGN-2605-X9069	PeptideMeter	2026-Q2	98.32	7.36	—	Buyer-sourced	PASS
AX-2026-041907	SinoPep	SNP-2605-G4075	Janoshik	2026-Q2	99.20	5.75	—	Buyer-sourced	PASS
AX-2026-043227	SGN	SGN-2605-X9069	PeptideMeter	2026-Q2	98.38	7.21	95.6	Buyer-sourced	PASS
AX-2026-041862	GSP	GSP-2605-K3362	Janoshik	2026-Q2	99.34	3.32	—	Buyer-sourced	PASS
AX-2026-041906	SinoPep	SNP-2605-G4075	Medutest	2026-Q2	98.94	5.28	—	Buyer-sourced	PASS
AX-2026-042346	Homopeptide	HOMO-2601-T3123	PeptideMeter	2026-Q2	99.70	3.47	—	Buyer-sourced	PASS
AX-2026-043229	SGN	SGN-2605-X9069	Janoshik	2026-Q2	98.21	7.43	—	Buyer-sourced	PASS

Other recent Homopeptide records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Result
AX-2026-042437	Retatrutide	HOMO-2605-V4718	Nordanalyt	2026-Q3	98.68	3.67	102.8	Buyer-sourced	PASS
AX-2026-042424	Semaglutide	HOMO-2604-X3806	PeptideMeter	2026-Q3	98.85	4.87	92.0	Buyer-sourced	PASS
AX-2026-042503	IGF-1 LR3	HOMO-2607-P5131	Janoshik	2026-Q3	99.36	5.99	—	Buyer-sourced	PASS
AX-2026-042492	SS-31 (Elamipretide)	HOMO-2604-D5484	Medutest	2026-Q3	99.93	2.40	—	Buyer-sourced	PASS
AX-2026-042491	SS-31 (Elamipretide)	HOMO-2604-D5484	Kestrel	2026-Q3	99.93	3.24	—	Supplier-supplied	PASS
AX-2026-042473	LL-37	HOMO-2602-G5165	Janoshik	2026-Q3	99.01	5.00	—	Buyer-sourced	PASS
AX-2026-042441	Retatrutide	HOMO-2605-V4718	Medutest	2026-Q3	98.93	4.22	—	Buyer-sourced	PASS
AX-2026-042474	LL-37	HOMO-2602-G5165	Janoshik	2026-Q3	99.18	5.44	—	Buyer-sourced	PASS